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ABSTRACT
The ongoing Zika virus (ZIKV) outbreak in Latin America, the Caribbean, and the Pacific Islands has
underlined the need for a coordinated research network across the whole region that can
respond rapidly to address the current knowledge gaps in Zika and enhance research prepared-
ness beyond Zika. The European Union under its Horizon 2020 Research and Innovation
Programme awarded three research consortia to respond to this need. Here we present the
ZikaPLAN (Zika Preparedness Latin American Network) consortium. ZikaPLAN combines the
strengths of 25 partners in Latin America, North America, Africa, Asia, and various centers in
Europe. We will conduct clinical studies to estimate the risk and further define the full spectrum
and risk factors of congenital Zika virus syndrome (including neurodevelopmental milestones in
the first 3 years of life), delineate neurological complications associated with ZIKV due to direct
neuroinvasion and immune-mediated responses in older children and adults, and strengthen
surveillance for birth defects and Guillain–Barré Syndrome. Laboratory-based research to unravel
neurotropism and investigate the role of sexual transmission, determinants of severe disease, and
viral fitness will underpin the clinical studies. Social messaging and engagement with affected
communities, as well as development of wearable repellent technologies against Aedes mosqui-
toes will enhance the impact. Burden of disease studies, data-driven vector control, and vaccine
modeling as well as risk assessments on geographic spread of ZIKV will form the foundation for
evidence-informed policies. While addressing the research gaps around ZIKV, we will engage in
capacity building in laboratory and clinical research, collaborate with existing and new networks
to share knowledge, and work with international organizations to tackle regulatory and other
bottlenecks and refine research priorities. In this way, we can leverage the ZIKV response toward
building a long-term emerging infectious diseases response capacity in the region to address
future challenges.
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Background
The 21st century has seen an unparalleled number of
emerging infections – the latest is the Zika virus (ZIKV)
epidemic in Latin America and South Pacific Islands [1].
The unusual neurotropism of this flavivirus resulting in
clusters of neurodevelopmental birth defects, further
compounded by clusters of severe neurological disease
in adults, triggered the World Health Organization
(WHO) to declare a public health emergency of interna-
tional concern (PHEIC) in February 2016. The ongoing
ZIKV outbreak has exposed the challenges associated
with the implementation of urgently needed research in
the Latin American region, and has underlined the need
for a coordinated research network across the whole
region that can rapidly respond to emerging threats.
Such a network would not only facilitate research to
investigate ZIKV but also be available to respond rapidly
to any future emerging threats in Latin America.
For this reason, in January 2016 the European
Commission announced a funding call, with the specifi-
cation to set up a research network across the Latin
America region to facilitate, coordinate and implement
urgent research against the current ZIKV outbreak, and
eventually lay the foundation for a preparedness research
network against any future emerging severe infectious
threats. The scope of the call can be found in Box 1: Call
Topic SC1-PM-22-2016. The submission deadline was
28 April 2016; on 21 October 2016 the European
Commission formally announced that three consortia
were awarded: ZikaPLAN (www.zikaplan.tghn.org),
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ZIKAction (www.zikaction.org), and ZIKAlliance (www.
zikalliance.tghn.org). Here we present ZikaPLAN, the
composition of the consortium and its objectives and
research design.
The ZikaPLAN initiative combines a multinational
and interdisciplinary consortium consisting of 25 insti-
tutional partners in Latin America, North America,
Africa, Asia, and various academic centers in Europe.
The institutions are listed in Box 2, and the geographic
distribution of the consortium is shown in Figure 1. The
hosting institution is Umeå University, Sweden and the
Scientific Coordinator and Scientific Co-coordinator
are Professors Annelies Wilder-Smith and Eduardo
Massad respectively with Dr Raman Kaur Preet as the
Executive Director. The project, the consortium, and its
main components have been designed with these dual,
complementary purposes in mind (Figure 2).
The consortium consists of experts with a broad
range of expertise covering virology, entomology,
arboviral diseases, clinical trial expertise, birth defect
surveillance, clinical cohort studies, pediatrics, neu-
rology, qualitative research, and communications.
Many of these experts already collaborated in a pre-
vious European Union (EU)-funded consortium
called DengueTools [2], and many experts in this
consortium serve as advisors to the WHO related to
Zika. Even prior to the EU research funding, many
consortium members had already conducted Zika
related work and published extensively on Zika
(check under ‘publications’ at: https://zikaplan.
tghn.org).
Box 2. List of institutions in ZikaPLAN
Participant no. Participant organization name Country
1 Umeå University Sweden
2 London School of Hygiene
and Tropical Medicine
UK
3 University of Glasgow UK
4 The Chancellor, Masters, and
Scholars of the University
of Oxford
UK
5 Queen Mary University of
London
UK
6 University of Ulster UK
7 Katholieke Universiteit Leuven Belgium
8 Erasmus Universitair Medisch
Centrum Rotterdam
The
Netherlands
9 Institut Pasteur France
10 Fundacion Universidad del
Norte
Colombia
11 Universidad del Valle Colombia
12 Fondation Merieux France
13 The University of Liverpool UK
14 La Jolla Institute for Allergy
and Immunology
USA
15 The University of North
Carolina at Chapel Hill
USA
16 Prins Leopold Instituut voor
Tropische Geneeskunde
Belgium
17 Fundacao de Apoio a
Universidade de Sao Paulo
Brazil
18 Instituto Butantan Brazil
19 Associao Tecnica-Cientifica
Estudo Collaborativo Latino
Americano de
Malformacoes Congenitas
Brazil
20 Fundacao Oswaldo Fiocruz Brazil
21 Instituto Medicina Tropical
Pedro Kouri
Cuba
22 Institut Pasteur de Dakar Senegal
23 Schweizerisches Tropen- und
Public Health-Institut
Switzerland
24 International Vaccine Institute Korea
25 Fundacao Universidade de
Pernambuco
Brazil
Box 1. Call topic SC1-PM-22-2016
Scope of the EU call:
The objective is to establish a multinational and multidisciplinary consortium across Latin America and other affected or at-risk regions, able
to implement the urgently needed research during the ongoing ZIKV outbreak. The proposal should address all of the following issues:
(i) The evaluation of the potentially causative relationship between ZIKV and the severe reported complications, as well as the exploration of
the mechanisms involved or of alternative aetiologies if needed. All relevant research is possible, ranging from basic research, research in
animal models, virology, and immunology studies, to a coordinated set of clinical studies (including for example prospective, cross-
sectional or retrospective epidemiological or cohort studies, supported by harmonized case definitions and the development of improved
ZIKV diagnosis and differential diagnosis assays, etc.) as necessary.
(ii) If such an association is confirmed, the consortium should be ready to rapidly launch additional studies (e.g. observational studies aimed
at establishing the natural history, pathogen and host determinants of severity of the disease, phase II or III interventional trials in
primary and/or secondary care aimed at providing evidence for potential prevention [including vaccines] and/or treatment strategies).
Depending on the evolution of the outbreak, the timeline of the proposed actions, and ZIKV research efforts implemented by other
stakeholders, the proposed action plan should maintain the flexibility to address remaining research gaps against ZIKV. This should
include the flexibility to include additional partners depending on the specific expertise required and/or the need to extend geographic
scope.
(iii) The consortium should further capitalize on the platforms established and the experience gained through this urgent ZIKV research
response, in order to evolve into a network capable of rapidly launching a research response to future severe infectious outbreaks caused
by emerging pathogens with pandemic potential or potential to cause significant damage to health and socioeconomics in the region [5].
Provisions should be made so that this initial research platform may be further developed through a comprehensive ‘interepidemic’
action plan addressing and fine-tuning the response to any obstacles identified during the ZIKV research response (e.g. resolving
regulatory and other bottlenecks, development of adaptable study protocols, strengthening ICT infrastructure for communication and
information exchange, developing a training programme to enhance the local partners’ capacity for laboratory and clinical research,
developing a communication strategy for patient and public engagement, etc.). A comprehensive data-management framework allowing
the standardized collection, storage, analysis, and sharing of data should be implemented, initially focusing on Zika data but eventually
evolving as a critical part of the preparedness research network. Additionally, a sustainability strategy that would enable the continuation
of the network beyond the timeline of the EU grant should be explored and developed during the project’s duration.
The consortium is expected to collaborate with relevant initiatives already-existing or under development at national, regional, and
international level, in order to maximize synergy and complementarity and avoid duplication of the research efforts. If more than one
proposal is successful, proposals should collaborate, and this should be indicated in the proposal.
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(A) Addressing ZIKA: we will address the current
knowledge gaps in ZIKV as requested in the call
topic: association with congenital syndromes and
neurological complications, clinical spectrum of dis-
ease, determinants of severe disease, pathogenesis,
and in particular neuro-pathogenesis, nonvector and
vector transmission, diagnostics innovation and eva-
luation, burden of disease, and risk factors for geo-
graphic spread; birth defect surveillance, social
science for communication strategies with affected
communities, novel personal preventive measures,
and modeling on vector control and vaccine strate-
gies for evidence-informed policies.
(B) Preparing for beyond Zika: While addressing
Zika, we will position the various activities and results
as a springboard toward building a sustainable Latin
American network capable of rapidly launching con-
certed, large-scale research responses to emerging
infectious diseases outbreaks of significant (potential)
impact to the region. This way, we can leverage the
Zika response toward building a long-term emerging
infectious diseases (EID) response capacity in the
region beyond the 4-year project period.
Concept and methodology
The project’s work plan is built on 15 interoperating
work packages (WP). The structural design of
ZikaPLAN reflects the ambition to address the urgent
research gaps (WP 1–8), identify short- and long-term
solutions (WP 9–10), and build a single sustainable Latin
American EID Preparedness and Response capacity, WP
11. Communications and consortium coordinated are
handled in WP 12 and 13 respectively. The project col-
laborates and interlinks with the two other EU-funded
Zika consortia, ZIKAction and ZIKAlliance on protocol
development, data sharing, joint data-analysis plans, and
biobanking, and aims to develop commonalities for the
dissemination of research findings (WP 14–15). Figure 3
presents the schematic work plan by WP. Box 3 sum-
marizes the primary research objectives of WP 1–12.
Description of WP
WP 1 Microcephaly Epidemic Research Group
(MERG): unraveling congenital Zika syndrome
WP 1 aims to address the main concern of ZIKV
infections that led to the declaration of a PHEIC:
adverse fetal outcomes. This work package is con-
ducted by the Brazilian MERG [3], which was estab-
lished in response to the first alert of microcephaly in
Recife/North-East Brazil in 2015 (University of
Pernambuco, London School of Hygiene and
Tropical Medicine), and is devoted to the clinical
recognition of congenital Zika syndrome. MERG
recruits pregnant women presenting with rash and
laboratory-confirmed ZIKV infection in a number of
sites in Brazil. Its objectives are to determine the
Figure 2. Dual purpose of ZikaPLAN.
Figure 1. Geographic distribution of the consortium.
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absolute risk of miscarriage, still birth, microcephaly,
and other clinical manifestations of adverse outcomes
to fetuses born to pregnant women with ZIKV infec-
tion by gestational age; and to define the full spec-
trum of congenital Zika syndrome at birth and the
subsequent manifestations and neurodevelopmental
milestones in the first 3 years of life [4–14]. This
will help develop an improved case definition of
congenital Zika syndrome for surveillance purposes
and birth-defect registries, and help us understand
the extent of disability and the social and economic
burden to affected families.
8
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Risk Assessment
1
MERG: unravelling
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Syndrome
2
NEURO-Zika:
neurological
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3
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4
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6
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7
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Figure 3. Schematic work plan by WP.
Box 3. Primary research objectives for WP 1–12
Addressing ZIKA:
Objective 1: To determine the (1) attack rate of CZS by gestational week of infection and (2) describe the full spectrum of CZS including
neurodevelopmental milestones in the first three years of life, and (3) evaluate the social impact on families
Objective 2: To define the spectrum of neurological diseases associated with ZIKV infection, in the central nervous system and peripheral nervous
system
Objective 3: To investigate the extent of and factors associated with sexual transmission of Zika in humans and mice models.
Objective 4: To discover and characterize the mechanistic pathways of ZIKV infection in the pathogenesis of CNS and PNS injury, focusing on (a)
direct viral invasion, and (b) immune and autoimmune responses to viral infection.
Objective 5: To develop and evaluate diagnostic tools for the diagnosis, surveillance, and research on ZIKV.
Objective 6: To identify the major T-cell epitopes and crossreactive B-cell epitopes on ZIKV and assess the role of flavivirus antibodies in protective
and pathogenic immunity following ZIKV through ADE.
Objective 7: To determine whether the contemporary ZIKV is associated with a higher viral fitness in Aedes aegypti mosquitoes and more severe
neurological disease and testicular involvement in mice compared with historical ZIKV.
Objective 8: To assess the seroprevalence in individuals aged 2–59 years in 14 different geographic locations in Brazil, and to document and model
regional and global geographic spread of ZIKV infections.
Beyond ZIKA:
Objective 9: To develop mathematical models to inform public health policies on how best to achieve vector control
Objective 10: To develop novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of
clothing and other wearable repellent technologies for the protection of pregnant women and nonpregnant individuals against Zika and other
Aedes-transmitted diseases
Objective 11: To establish a Latin American and Caribbean network together with the other two EU-funded Zika consortia for EID preparedness to
support a rapid and coherent research response to the ZIKV outbreak in the short term, and to other vector-borne and emerging infectious
disease outbreaks in Latin America in the long term.
Objective 12: To develop social messaging for women of reproductive age.
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WP 2 neuro-Zika: neurological manifestations of
Zika
The ‘Neuroviruses Emerging in the Americas
Study’ (NEAS) is a multicentre study in the
Americas (NCT03206541) to establish a compre-
hensive registry of the clinical, radiologic, and
paraclinical profile of patients with new onset of
neurological diseases associated with Zika, dengue
and chikungunya viruses (http://www.neasstudy.
org/en/home/) with a network involving more
than 10 hospitals in Colombia. NEAS was initiated
by Prof. Carlo Pardo-Villamizar from Johns
Hopkins University, US, and has already resulted
in various publications [15–17]. The NEAS network
will be enhanced by various additional sites in
Brazil. The main objective is to define the full
spectrum of neurological complications due to
ZIKV by using a case-control study design. This
potential spectrum includes immunologically
mediated illness, for example Guillain–Barré syn-
drome (GBS) or acute disseminated encephalomye-
litis (ADEM), and direct viral invasion of the
nervous system for example meningoencephalitis
and neuropathies. The International GBS outcome
study (IGOS) https://gbsstudies.erasmusmc.nl/,
based at Erasmus University, the Netherlands, will
adapt some of its protocols to the Latin American
context and make them widely available to neurol-
ogists and expand the network to increase the
number of participating hospitals so that improved
case-management protocols, larger sample sizes for
biomarker studies, and a coordinated and harmo-
nized effort for well-designed studies will be
achieved that will benefit Latin America beyond
the immediate response to ZIKV. Several investiga-
tors in this work package are members of the
WHO Guideline Development Group for GBS and
other neurological diseases associated with ZIKV,
and are experts in the clinical care and manage-
ment of patients with GBS and other neurological
sequelae of central nervous systems (CNS) viral
infection. The implementation of the research in
this work package will strengthen the management
of these conditions across Brazil and Colombia,
working in conjunction with the WHO Expert
Panel for ZIKV infections. For example, clinical
guidelines for the harmonization of management
of patients with Neuro-Zika across Latin America
will be produced.
WP 3 nonvector transmission in humans and mice
models
The incidence rate of ZIKV semen infection in male
returning travelers with laboratory confirmed ZIKV
infection will be determined as a proportion of the
total number of included men with confirmed ZIKV
infection. The replication fitness of ZIKV in semen
will be explored by isolation of ZIKV virions in
culture. The persistence of ZIKV in semen after
acute infection will be analyzed semiquantitatively,
and the incidence of secondary cases reported.
Furthermore, this WP will establish a ZIKV mouse
model for sexual transmission and study the path-
way of entry of the virus via the vaginal route.
Furthermore, a vertical transmission mice model
will be developed to study whether an infected
fetus contributes to higher viremia in the mother.
WP 4 neuropathogenesis
WP 4 will investigate pathomechanisms of neuro-
tropism in the laboratory through a combination
of approaches in virology, animal studies, neu-
roimmunology, cellular neuroscience, and host–
virus interaction studies including neural recep-
tors. Through close integration and specimen
sampling through WP2 enhanced by mice models,
the specific objectives are: (1) to define Zika virus
tropism in the peripheral (PNS) and CNS in vitro
and in vivo; (2) to determine the consequences for
PNS and CNS cell health, function and survival of
direct ZIKV infection, in vitro and in vivo; (3) to
investigate intra- and intercellular trafficking of
ZIKV within and between the periphery and the
PNS and CNS; (4) to characterize the nature of
ZIKV’s main cellular receptors on human neural
cells, screening proteins, glycoproteins, proteogly-
cans, glycolipids, and thereby identify candidates
used by ZIKV to attach to neural cells; (5) to
determine if humoral factors from Zika-GBS
patient and control sera are pathogenic to PNS
and CNS cells in vitro and ex vivo; (6) to examine
sera from Zika-GBS cases and controls for antigen
targets known to be associated with conventional
GBS, principally peripheral nerve glycolipids,
using sensitive immunoassays; and lastly (7) to
examine differential immune responses in patients
with nonneurological ZIKV infection, patients
with viral invasion of the CNS (e.g. encephalitis),
and patients with autoimmune neurological dis-
ease. Understanding the intricate relationships
between direct neuroinfection and postinfection-
related neural autoimmunity, and exploring the
scientific principles that underpin the clinical phe-
notypes associated with this dichotomization will
have a profound impact on developing approaches
to diagnosis, treatment, and vaccine development.
We hope to identify relevant biomarkers, and pos-
sibly neural receptors – which could be potentially
exploited for prognostic use (biomarkers) or ther-
apeutic intervention (targeting neural receptors).
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WP 5 platform for diagnostics innovation and
evaluation
The platform for diagnostics innovation and evalua-
tion is a major focus of ZikaPLAN. Regarding diag-
nostics innovation, we aim to identify the major type-
specific and cross reactive B-cell epitopes on ZIKV
for development of minimally cross-reactive IgM and
IgG for more specific serological assays. We also hope
to identify monoclonal antibodies to NS1 antigen for
the potential development of a NS1 based assay – all
with the aim to develop novel ZIKV diagnostic tests
in accordance with WHO Target Product Profiles.
Our evaluation platform will be based upon well-
characterized archived specimens obtained by
informed consent, in accordance with the protocols
developed by the WHO prequalification program
for this purpose. All the evaluation sites will be
compliant with the principles and practice of
Good Clinical Laboratory Practice (GCLP). Assays
that fulfill the target performance set by WHO will
be selected to proceed to clinical performance stu-
dies, which will be conducted at our virtual network
laboratories that include the Pan American
Laboratory Network for Dengue and other arbo-
viruses, RELDA (which comprises 18 laboratories
in Latin America and five in the Caribbean), the
WHO collaborating center for arboviral diseases in
Senegal (IPD), ITG Antwerp, and the International
Vaccine Institute Korea (IVI) – all with access to a
geographic diversity of samples to test for cross-
reactivity against an array of diverse flaviviruses.
Samples from these sites will form a virtual biobank
with a strict code of governance on the use of
samples to facilitate test development, evaluation,
and research. A manual and standard operating
procedures on sample collection and characteriza-
tion will be developed to ensure harmonization of
bio-banking procedures. This platform will be used
for evaluation of commercially developed new diag-
nostic assays (at a fee) and will be free to the wider
academic community under certain contractual
conditions. The evaluation results will be provided
to WHO for prequalification and regulatory autho-
rities in countries for approval.
WP 6 INVADE: investigating vaccines in antibody-
dependent enhancement
‘INVADE’ sets out to carry out T-cell and B-cell
epitope mapping, and assess the role of flavivirus
antibodies in protective and pathogenic immunity
and the role of antibody-dependent enhancement
(ADE) [18]. In particular, the aim is to define the
epitope breadth/repertoire and the targets of CD4
and CD8 responses; to derive sets of HLA class I and
class II predicted epitopes covering the entire ZIKV
proteome; to define phenotypes and T-cell subsets
associated with CD4 and CD8 specific T cells; to
identify the major type-specific and crossreactive
B-cell epitopes on ZIKV, and to assess the role of
flavivirus antibodies in protective and pathogenic
immunity (e.g. related to prior dengue infections,
dengue, and yellow fever vaccines). More than
2000 T-cell epitopes [3,4] and epitopes targeted by
type-specific neutralizing, nonneutralizing, and pos-
sibly enhancing/autoimmune reactive antibodies
will be identified, which may help develop vaccines
and study potential mechanisms of immune patho-
genesis responsible for severe neurological and fetal
defects.
WP 7 viral fitness: current versus historic ZIKV
The aim of WP 7 is to investigate whether ZIKV
emergence is associated with adaptive viral evolution
in the vector, i.e. viral fitness differences that may
explain the observed recent increase in ZIKV trans-
mission by mosquitoes among humans. We will also
address whether contemporary ZIKV result in more
severe neurological disease, different tissue tropism,
and higher viral loads in mice compared with historic
ZIKV isolates.
WP 8 ‘disease burden and risk assessment’
This WP assembles a wealth of data obtained from
various sources, including a longitudinal cohort study
of 17,000 subjects aged 2–59 years in 14 different
geographic locations in Brazil over 3 years, recruited
through an ongoing Phase 3 trial by ZikaPLAN
Partner Butantan. Seroprevalence studies will help to
assess the asymptomatic to symptomatic ratio, the age-
and gender-stratified attack rates, the clinical spec-
trum, and the impact of preceding dengue infections
on the severity of illness. Documentation of the evol-
ving epidemiology of ZIKV will be enriched by data
from the Latin American network on birth-defect sur-
veillance (ECLAMC). We will establish an
‘International Committee for Birth Defect
Surveillance Tools for Infection Disease Response
Preparedness’. This will consist of representatives
from four birth-defect surveillance networks with
expertise in this area: The European network of popu-
lation-based congenital anomaly registries
(EUROCAT), ECLAMC (Latin America), both of
which are ZikaPLAN partners, and the International
Clearinghouse for Birth Defects (ICBDSR), and Centre
for Disease Control (US). A detailed inventory of Birth
Defect Surveillance Tools will be made available on
The Global Health Network (TGHN) web platform. A
new Tablet App will be produced, tested, and used for
the diagnosis and coding of birth defects in low-
resource settings with good access to pediatricians.
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The App will contain atlas/picture material, diagrams
created digitally by a medical illustrator, the
International Classification of Disease Codes version
10, training videos, and guides. A specific ‘Zika mod-
ule’ will also be created. The App will be an important
part of the sustainability in terms of globally available
tools for infectious disease preparedness and the sur-
veillance of birth defects in low-resource settings.
The Swiss Tropical and Public Health Institute
(Swiss TPH) will establish a smartphone-based senti-
nel surveillance system in travelers to Latin America
and other Zika-affected countries in order to assess
the incidence of Zika-/arboviral-related symptoms in
travelers, trace and diagnose these travelers, and
assess the risk of zika/arbovirus introduction to a
vector-infested region of Europe (Barcelona, Spain).
Swiss TPH will also develop baited filter-paper-based
mosquito traps for the collection of mosquito saliva
in tropical and subtropical countries (using interna-
tional travelers), in order to assess the arbovirome of
the local mosquito populations.
The results from our partners and this work pack-
age, further enhanced by literature reviews, will feed
into mathematical modeling to document and predict
burden of disease in Latin America. Complemented
by data from GeoSentinel, Healthmap, and Bluedot,
we will analyze the geographic spread of Zika infec-
tions beyond Latin America. Much of this will involve
modeling spread via air passengers [19,20]. We will
apply previously developed models for the risk of
dengue spread via air passengers [21–23] to model
the spread of ZIKV. We already modeled the risk of
ZIKV infection during the Olympics [24,25] and pro-
vided input to the WHO IHR committee not to
cancel the Olympics. We also published the most
likely time of ZIKV introduction into Brazil based
on mathematical modeling [26].
WP 9 mathematical modeling to inform public
health policies
Here, we will model best vector control strategies for
high-population-density areas in Latin America. To
this end, work on vectorial capacity of Aedes mosqui-
toes for Zika in temperate countries has already been
conducted by the ZikaPLAN team [27]. Modeling
ecological, climate, and mobility patterns will assist
in enhancing appropriate public health responses
[27–29]. We will model vector-control strategies
(Wolbachia/genetically modified mosquitoes) to
inform optimal control bundles to mitigate future
outbreaks, in particular in Latin American cities.
Furthermore, this WP aims to establish mathematical
models on the role of sexual transmission in coun-
tries without Aedes aegypti/albopictus mosqui-
toes [30].
We will also build a community of practice related
to vector control. This community of practice for
vector-control groups will be called The Global
Vector Hub and will be located within the TGHN
digital platform to maximize visibility and uptake,
and also to provide users with access to further
tools and resources that can support their research
and teams. The community of practice for vector
control is focused on supporting and linking
researchers working with mosquitoes through a digi-
tal infrastructure where they can share tools and
resources in order to deliver training, raise capacity,
and establish standards. Enhancing vector-control
strategies through such a community of practice will
benefit ZIKV control but also other mosquito-borne
diseases.
WP 10 WEAR: wearable Aedes-repellant
technologies
‘WEAR’ aims to develop personal protective measures
for pregnant women (impregnated maternity clothing
for example). We will investigate and develop novel
detergents containing repellents that can be used dur-
ing laundry to allow active repellents to be applied to
clothing for protection and also investigate new wash-
resistant technologies, including novel silica-shell,
polymer fibers, and microencapsulated formulations
to determine whether repellent active ingredients can
be retained in fabrics for multiple washes. New plastic
wearable repellent technologies will be developed and
tested, including flip flops, wrist bands, and necklaces
using a plastic silica technology for protection against
Aedes spp. mosquitoes. Qualitative research will be
conducted to assess the acceptability of such clothing
and technologies.
WP 11 ZIKA collaborative establishment of a
Latin American preparedness network (PLAN)
‘PLAN’ led by TGHN at Oxford University will ensure
that the consortium, networks built, activities per-
formed, and results obtained are leveraged into estab-
lishing a Latin American EID Preparedness and
Response network in the region beyond Zika. To this
purpose, we will work together with ZIKAlliance and
ZIKAction in order to leverage synergies, in particular
with regard to the clinical cohort studies. A specific
platform will be set up to enhance the outreach to
expand to new sites and to develop into an independent
research network beyond the project time. This is called
REDe (the Spanish and Portuguese term for network),
which will be a shared and open space for information
exchange and releasing research documents such as
protocols and operating procedures, to ensure standard
outcome measures are used, to optimize data sharing,
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and also to disseminate the research tools in order that
others may use and adapt them. REDe is hence a
research-capacity development and knowledge-
exchange space for all three EU-funded Zika consortia
and their clinical sites. The bottlenecks that we will
identify throughout the project are likely to be some-
what similar to those encountered in Europe, and we
will therefore also liaise with EU funded Platform for
European Preparedness Against (Re-)emerging
Epidemics (PREPARE) to incorporate lessons learned
through their preapproval processes of epidemic clinical
research protocols.
Research needs to be embedded into a response to an
outbreak or emerging disease [31], and to achieve this
there needs to be local ability to undertake study design
and operation to gather the high-quality evidence that is
rapidly needed [32]. TGHN will be harnessed as a
respected online platform for research education, train-
ing, and resources for capacity building in Latin America
as the host of the REDe network. The aim of REDe is to
link together and work with experienced and inexper-
ienced research sites across Latin American and the
Caribbean to deliver knowledge, research tools, and
training. The underlying philosophy is that if there is to
be a locally led and rapid research response in an out-
break, then the local ability to undertake the collection of
high-quality research data needs to be built up. A wide
range of cross-cutting research resources and tools will
be provided, such as free online seminars and courses,
downloadable training kits, articles, templates and gui-
dance notes, in particular linkage to IGOS, ECLAMC,
and diagnostics. Harmonized web-based tools for birth-
defect registries will be accessible. Other tools such as
‘SiteFinder’, an application that allows partners planning
studies to find new sites to collaborate with, are also
freely available and easily accessible. The training center
already provides translated core courses such as Good
Clinical Practice, GCLP, and Bioethics, as well as broader
topics such as ‘Introduction to Clinical Research’ and
‘Children and Clinical Research’. Alongside these
resources and training, there will be a whole set of
regionally based activities and support systems to provide
opportunities for research staff from a specific region to
meet, learn, and share experiences.
WP 12 dissemination and communication
ThisWP will develop and implement a detailed commu-
nication and dissemination plan serving as the central
consortium-wide guiding document for how we deal
with dissemination and communication with our stake-
holders. These stakeholders include international and
national governmental organizations/health authorities/
funders in the area of EIDpreparedness and response, e.g.
WHO, PAHO, PREPARE, and Global Research
Collaboration for Infection Disease Preparedness
(GLoPID-R). Engagement with affected communities,
in particular pregnant women, including social messa-
ging of personal protection, will also be central toWP 12.
Following qualitative research in North-East Brazil sup-
portive, actionable messages will be developed that take
data on burden of disease into account. These social
messages will be based on an empirical understanding
of people’s perceptions and concerns about Zika and will
be built on the lessons learned from the Zika-related
messages that have been used to date, in particular with
those coordinated by WHO (http://www.who.int/emer
gencies/zika-virus/en/)
WP 13 consortium coordination and management
Umeå University, Sweden under WP 13 will coordinate
all the collaborative efforts and facilitate communication
within the consortium. It will set up an effective manage-
ment framework to ensure progress toward its planned
objectives reflecting our contractual commitments to the
European Commission.
WP 14 Zika data share: harmonization of data
and roadmap to data sharing
The aims of the work package are (1) to ensure harmo-
nization of protocols and standardization of tools
(including data dictionaries) for the multicentre preg-
nant women and children cohort studies across the
three EU-funded Zika consortia (ZikaPLAN,
ZIKAction, ZIKAlliance); (2) to conduct data sharing
within the three consortia and to provide a roadmap
toward wider data sharing. The pregnant women cohort
is harmonized between ZIKAction and ZIKAlliance (as
both recruit asymptomatic and symptomatic pregnant
women), whereas ZikaPLAN recruits only women symp-
tomatic ZIKV infection during pregnancy. The data
garnered through these combined cohorts will also feed
into the WHO-led ‘individual participant data meta-
analysis (IPD-MA)’, which will combine de-identified,
participant-level cohort data to identify and quantify the
relative importance of different predictors of congenital
Zika syndrome (CZS) (www.who.int/entity/reproductive
health/projects/ZIKV.pdf). Individual participant data
(IPD) allow for more consistent control of confounders
and facilitate the assessment of effect measure modifica-
tion and sensitivity analyses that would not have been
possible if we did not combine the data obtained from
the three EU-funded consortia and other consortia or
research groups with similar cohort studies. Under the
guidance of WHO, the use of IPD will allow us to fully
explore subject-level sources of heterogeneity in the asso-
ciation between congenital ZIKV infection and preg-
nancy complications, and will facilitate the
identification of the subgroups of women at the highest
risk of experiencing ZIKV-related pregnancy
complications.
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WP 15 ZIKA-COLLAB
The overall objective is to enhance the output of the
respective EU-funded Zika consortia through shared
management structures and communications activities,
create and maintain joint management and oversight
structures, and address ethical and information govern-
ance issues, ensuring ethical and safe care and treatment
of animals and use of patient data and samples for
research across and potentially outside of participating
consortia. We will organize integrated communications
across consortia, including the creation of a
Communications Oversight Board, planning of joint
meetings, and organization of cross-consortia working
groups to ensure clear, coherent messages that integrate
all communication and dissemination activities. Ethics
is an integral part of research from beginning to end,
and ethical compliance is pivotal to achieve real
research excellence (http://ec.europa.eu/research/parti
cipants/data/ref/fp7/89888/ethics-for-researchers_en.
pdf). Within the European regulatory framework,
research ethics is based on the explicit European com-
mitment to human rights. We therefore established a
joint Ethics Advisory Board for the three EU-funded
consortia, which will provide oversight and advice over
ethical issues pertaining to our human and animal
studies.
Outlook
The speed in research response after the declaration
of the PHEIC in 2016 was unprecedented. As the
ZIKV outbreak is rapidly waning in 2017, it is even
more significant that the Consortium should further
capitalize on the REDe platform established in WP 11
and the experience gained through this ZIKV
research response, in order to evolve into a network
capable of rapidly launching a research response to
future severe infectious outbreaks caused by emer-
ging pathogens.
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and birth defect has been established, but many other
research gaps exist.
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fitness, conduct burden of disease studies, and model out-
break responses. We will also build up research capacity in
the region.
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